The Impact of Vitamin K2 on Energy Metabolism by Møller, Mona et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
Chapter 5
The Impact of Vitamin K2 on Energy Metabolism
Mona Møller, Serena Tonstad, Tone Bathen and
Jan Oxholm Gordeladze
Additional information is available at the end of the chapter
http://dx.doi.org/10.5772/67152
© 2016 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons 
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, 
and reproduction in any medium, provided the original work is properly cited. 
The Impact of Vitamin K2 on Energy Metabolism
Mona Møller, Serena Tonstad, Tone Bathen 
and Jan Oxholm Gordeladze
Additional information is available at the end of the chapter
Abstract
Environmental and behavioral adaptations introduced during the last decades have 
synergistically enhanced man’s lifespan, but also paved the ground for disease states 
involving impairment of multiple organs, which are both modulating and depending on 
homeostatic calorie “accounting.”
Diabetes, obesity, and/or bone brittleness now occur frequently in our society, inducing 
ailments affecting overall health and well-being. Therefore, an improved comprehension of 
how organs (e.g. bone and adipose tissue) may provide homeostasis and sound strategies 
to treat these diseases, thus improving health and life quality of most age categories, should 
be sought. The steroid and xenobiotic receptor (SXR) (pregnane X receptor = PXR) is a 
nuclear steroid-like hormone receptor, stimulated by hormones, steroids, drugs, and xeno-
biotic compounds. SXR exhibits a versatile ligand binding domain, serving as a xenobiotic 
sensor, regulating xenobiotic clearance from the liver and intestine. However, new and 
interesting functions of SXR in the regulation of inflammatory processes, cholecalciferol 
and bone metabolism, lipid and energy homeostasis, and cancer therapy, have emerged.
Hence, the discovery and pharmacological development of new PXR modulators, like 
vitamin K2, represent an interesting and innovative therapeutic approach to combat 
 various diseases, of which glucose and lipid metabolism (i.e., energy metabolism and 
adiposity) should be emphasized.
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1. Introduction
In the past years, we have seen a plethora of research reports illuminating the link between 
bone physiology and energy metabolism, even though the central and sympathetic nervous 
© 2017 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
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systems, but also the gastrointestinal and pancreatic axes serve essential functions related 
to the systemic regulation of energy expenditure. It may be asserted that the fat tissue is 
more prominent due to its basic implication in storing and dissipating energy. During the last 
25 years, a major progress has been communicated within the medical societies, featuring a 
modern understanding of the origin of fat tissues, their specialized characteristics and func-
tioning, as well as the pathophysiological consequences of their impairment. These advances 
consequently lead to the discovery that adipose tissue metabolism is heavily coupled to the 
homeostasis of the skeleton.
Fat tissue is able to deposit and releases energy rich compounds during feeding and fasting, 
respectively, and it modulates the energy homeostasis in a versatility of organs via its endo-
crine potential. Fat cells (adipocytes) may accumulate energy in the form of triglycerides, as 
well as burning it by degrading fatty acids via so-called β-oxidation. Additionally, adipocytes 
produce and release so-called adipokines, among which leptin and adiponectin are the most 
important ones. These hormones regulate both the ingestion of calories, as well as the body’s 
sensitivity to insulin. The functional multiplicity of adipose tissue is sustained by various 
subtypes of adipocytes in depot storing fat. Mitochondria-sparse white adipose tissue (WAT), 
characterized as visceral and subcutaneous fat, stores energy as triglycerides for which the 
level is regulated by the body’s sensitivity to insulin and the overall metabolism of glucose in 
the liver and skeletal muscle cells, respectively. Contrastingly, mitochondria-enriched brown 
adipose tissue (BAT), which in adults is positioned as discrete entities localized in the neck 
and other regions of the trunk of the body [1], serves to dissipate energy to sustain adaptive 
thermogenesis [2]. This process is facilitated by the action of uncoupling protein 1 (UCP1), 
stimulating a leakage of protons, in order to uncouple respiration from ATP synthesis, thus 
favoring heat production. The thermogenesis sustained by BAT is mastered via the central 
nervous system, the impact of both the signaling systems comprised by catecholamines (i.e., 
β-adrenergic signaling), as well as deiodinase 2 (Dio2)-facilitated thyroid hormone conver-
sion from T4 (thyroxine) to T3 (triiodothyronine). As an extra feature, compared to its role 
in adaptive thermogenesis, BAT is also protecting against obesity, as well as against insulin 
resistance and development of diabetes [5–8]. Finally, it is worth noticing that genetic ablation 
of BAT in small experimental animals is resulting in diet-induced obesity, diabetes mellitus 
with insulin resistance, as well as enhanced blood lipids [3].
It has been asserted that BAT may originate from two sources. The classical or ordinary, 
preformed BAT stems from Myf5-positive dermomyotomal progenitor cells which may also 
yield skin and muscle, as well as functioning in so-called nonshivering thermogenesis [4]. 
On the other hand, Myf5-negative progenitor cells may differentiate into white adipocytes 
which play a role in energy storage, or to BAT-like or “beige” fat cells. The latter adipocytes 
demonstrate both brown and white fat cell characteristics [5]. Of major importance is the 
fact that BAT-like adipocytes can be transformed into WAT-like adipocytes through a pleth-
ora of mechanisms, of which a few deserves mentioning; cold exposure, endocrine action 
of FGF21 [6] or irisin [7], and via transcriptional regulators including FoxC2 [8], PRDM16 
[9], and PPARc [10], which lead to SirT1-mediated deacetylation of the PPARc protein 
[11]. Beige fat possesses powerful antiobesity and antidiabetic activities. An overexpres-
sion of BAT-specific transcription factors, i.e., either FoxC2 or PRDM16 in WAT adipocytes, 
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has been shown to protect mice from diet-induced obesity and metabolic dysfunction [9]. 
Furthermore, ablation of beige fat cells by adipocyte-only deletion of the transcriptional 
modulator PRDM16, yields experimental animals, which become prone to diet-induced 
obesity and ensuing insulin resistance [12].
In line with the cited article published by Lecka-Czernik et al. in Archives of Biochemistry 
and Biophysics, 2014 [13], we performed the following experiment: Human adipose stem 
cells and 3T3-L1 preadipocytes, the latter with an activated mutation (ref) in the Gi2α-protein were differentiated into fully mature adipocytes as indicated by coloration with Alizarin 
Red. Interestingly, both adipocyte species accumulated triglycerides upon differentiation to 
mature adipocytes; however, exposure to vitamin K2 (MK-7) diminished their ability to turn 
into fully mature adipocytes. Furthermore, both adipocyte species were tested for expression 
of various genes differing white adipocytes from beige adipocytes. From the gene expres-
sion profile, featuring genes like the beta-adrenergic receptor β3-AR, Foxc2, PGC1α, PPARα, 
Dio2, UCP1, Adipoq, and Leptin, it was quite obvious that the preadipocytes in question 
differentiated more in the “direction” of beige, lipid (or fatty acid) metabolizing adipocytes 
than into white, triglyceride-storing adipocytes. Hence, it could be concluded or hypoth-
esized that vitamin K2 (MK-7), in fact, was able to direct preadipocytes into becoming an 
energy-dissipating, rather than energy-storing adipocyte phenotype (see Figure 1, left and 
right panels). A putative model featuring this development, referring to a suggested mecha-
nism, is given in Figure 2.
Here, we have demonstrated that vitamin K2 affects the differentiation of preadipocytes to 
mature adipocytes, ensuring that the “end-point” phenotype may be tilted in the direction 
of the beige, energy “dissipating” phenotype. In their paper from 2014, Lecka-Czernik and 
coworkers [13] assert that an impairment in fat function correlates with a reduced bone mass 
and an increased incidence of fractures. But, the question posed by the authors is: does accu-
mulation of bone marrow adipose tissue (BMAT) exert a detrimental effect on bone structure 
and or mineralization, and will a diminished bone mass stimulate the accumulation of BMAT? 
Historically, BMAT was construed as a dormant or inert type of fat that accumulated within 
the bone marrow in order to pose as empty space filling subsequent to involution of hemato-
poietic tissue. Hence, its relationship with a lower bone mass was construed as circumstantial. 
However, novel evidence asserted that marrow adipogenesis should be construed as a pro-
cess, which is tightly bound to the differentiation of osteoblasts, since they “share” common 
precursor cells, and they are subjected to same modulatory signaling patterns. This yields, 
however, opposite end results where a positive correlation with an overall fat metabolism 
indicates that BMAT, in fact, actively induces bone mass loss and inferior quality.
Both, over and malnutrition represent systemic changes in energy metabolism, affecting bone 
fat volume and bone mass. Despite the fact that adipose (overweight) individuals present with 
a higher body weight, the more often than not demonstrate a lower BMD. In obese older men 
and women, an enhanced percentage of body fat and low amount of lean (muscle) mass pre-
dicts a lower BMD and thus an enhanced frailty risk [14]. The enhanced fracture risk incurred 
by postmenopausal women and older men [15] is mainly due to enhanced circulatory levels 
of adipose tissue derived in adiponectin and proinflammatory cytokines, with a concomitant 
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lower secretion of leptin and IGF-1. Furthermore, one will often detect lowered blood levels of 
25-hydroxyvitamin D and higher serum parathyroid hormone levels in these “patients” [15].
Figure 1. Human adipose stem cells and mutated 3T3-L1 preadipocytes were differentiated towards mature 
adipocytes. Top panel: Control cells are not manipulated with differentiating medium show lack of ability to store lipids 
(no Alizarin Red accumulation). Cells are differentiated in the presence of insulin, as well as IBMX (an inhibitor of 
phosphodiesterase) accumulate lipids, while cells are also exposed to vitamin K2 (MK-7) and lose their ability to produce 
and store triglycerides. Bottom panel: Percentage modulation relative to the “control” stage seen with exposure of human 
adipocytes and mutated 3T3-L1 cells to differentiating medium versus exposure to vitamin K2 (MK-7). Cells treated 
with vitamin K2 exhibit significant increments in genes characterizing beige adipocytes, where the alterations in PGC1α, 
PPARα, PPARγ, Dio2, and UCP1 expression were more prominent.
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2. Vitamin K2 and its mechanism of action – beyond xenobiotic 
metabolism
The steroid and xenobiotic receptor (SXR), which is synonymous with the pregnane X recep-
tor = PXR, is characterized as a nuclear hormone receptor that is stimulated by a plethora 
of hormones, dietary steroids, pharmaceutically active agents, as well as xenobiotic com-
pounds. SXR exhibits a binding domain, which diverges across mammalian species. SXR 
is construed as a xenobiotic sensor, facilitating xenobiotic clearance in the liver and intes-
tine. However, newly published experiments unravel novel roles for SXR in modulating 
phenomena like inflammation, bone turnover, metabolism of vitamin D, lipid, and energy 
homeostasis, as well as cancer. The characterization of SXR as conveyer of hormone-like 
signals has now been recognized as a key instrument for the study of novel mechanisms, 
through which diet may ultimately affect health and disease. The discovery and pharmaco-
logical development of new PXR modulators, like vitamin K2, might represent an interest-
ing and innovative therapeutic approach to combat various ailments and diseases.
Figure 2. Putative model system featuring the mechanism behind the impact of vitamin K2 (MK-7). Based on previously 
published consensus material, our new findings of the effect of vitamin K2 (MK-7) shows that K2, via binding to the 
transcription factor PXR/SXR affects several signaling molecules and/or pathways, via the β3-adrenergic system, 
impinging on signaling molecules like PKA, PGC1α, C/EBPβ, and Dio2, which eventually affects the activity of the 
uncoupling protein UCP1, which produces heat (and not ATP) from fatty acids. Not mentioned in the text is the reciprocal 
regulatory loop consisting of the microRNA species hsa-mir-155 and the transcription factor C/EBPβ, which can be 
manipulated to reinforce the “beige” phenotype of the adipocyte after differentiation from the stem cells or preadipocytes.
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Without elaborating on the details of how different natural products modulate the activity 
SXR to affect gene expression, it should be noted that St. John’s wort (hypericum perforatum), 
vitamin E (tocopherols and tocotrienols), as well as sulforaphane and Coleus forskohlii, the 
latter producing forskolin which is able to stimulate adenylate cyclase activity, suffice to say 
that K2 emerges as an interesting “player” on the scene featuring major metabolic pathways 
accounting for a plethora of actions to be reckoned with [16]. One good example is the effect of 
SXR activation on the metabolism of cholesterol and lipid turnover, a second one is its impact 
on the Fox transcription factors (i.e., FoxO1 and FoxA2), and their influence on energy homeo-
stasis [16]. FoxO1 and FoxA2 are both members of the “forkhead” family tree of transcription 
factors, serving critical roles in both lipid metabolism, as well as gluconeogenesis in the liver 
[17]. FoxO1 stimulates hepatic gluconeogenesis during fasting through the activation of glu-
coneogenic genes, such as PEPCK1 (phosphoenolpyruvate carboxykinase 1), G6P (glucose-
6-phosphatase), as well as and insulin-like growth factor-binding protein 1.
FoxA2, on the other hand serves as a key switch, representing one of the regulatory factors of 
the breakdown of hepatic fatty-acids during calorie-restriction (i.e., fasting). Via mammalian 
cell-based two-hybrid screening, it was feasible to identify FoxO1 as a coactivator of both 
CAR (constitutive androstane receptor)-mediated, as well as SXR-stimulated transcription 
[18]. FoxO1 may directly associate with CAR and SXR as a hormone-ligand-receptor complex 
and stimulate their transcriptional ability. And, both CAR and SXR function as corepressors of 
FoxO1, suppressing the FoxO1-mediated transcription by counteracting its association with 
its response elements within the susceptible genes. As well as obliterating the FoxO1 activity, 
drug-stimulated SXR and CAR species were also shown to downregulate HNF4α transcrip-
tional power via suppression of PGC1α, thus suppressing the transcription of both PEPCK1 
and G6P [19]. This indicates that metabolic turnover of both drugs and glucose, the two major 
functions of the liver which are regulated independently, happens to be reciprocally coregu-
lated via communication between xenobiotic sensors on one hand, and transcription factors 
in the liver, on the other. When blood sugar concentrations are rendered low due to fasting 
or subsequent to periods of exercise, the liver funnels energy rich molecules to extra-hepatic 
tissues and peripheral organs via either β-oxidation or the production of ketone bodies [20]. 
FoxA2 is stimulating both ketogenesis and β-oxidation via enhancement of the transcriptional 
activity of a plethora of genes, such as mitochondrial 3-hydroxy-3 methylglutarate-CoA syn-
thase 2 (HMGCS2) and carnitine palmitoyltransferase 1A (CPT1A) in energy-depleted condi-
tions (fasting), or subsequent to periods where extensive exercise prevails [21].
FoxA2 is phosphorylated and thus inactivated by the Akt pathway, and serves to decrease 
lipid turnover in response to insulin. Treatment with other drugs such as barbiturates has been 
shown to suppress lipid metabolism in an insulin-independent fashion [22]. Furthermore, it 
was reported that SXR may crosstalk with FoxA2 in order to induce the repression of lipid 
turnover in livers of fasting mice. By applying wild-type and SXR-/- animals, it was demon-
strated that treatment with PCN (pregnenolone-16d-carbonitrile) diminished the steady-state 
mRNA levels of HMGCS2 and CPT1A in control animals, but not in SXR-deficient mice. When 
conducting biochemical and cell-based analyses, it was shown that SXR markedly downregu-
lates the ability of FoxA2 to bring about activation of the HMGCS2 and CPT1A genes. SXR 
that serves as the ligand binding domain will associate directly with the DNA-binding area of 
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FoxA2, and the ensuing interaction will halt the “coupling” between FoxA2 and its response 
in DNA elements. The communication between SXR and FoxO1/FoxA2 signifies that SXR, 
apart from being a modulator of drug metabolism in the liver, is also serving as an important 
regulator in hepatic in glucose and energy homeostasis. Hence, since vitamin K2 binds to and 
enhances SXR-mediated transcription, it may serve as the natural “drug” to ingest, when one 
is aiming to treat insulin resistance and type II diabetes mellitus. The impact of vitamin K2 
via SXR on the metabolic functions in general, is described in more detail in the forthcoming 
paragraphs (“SXR in glucose handling” and “SXR in lipid turnover”) [22].
In Figure 3, we show our own experiments indicating that the adipocyte phenotype, char-
acterized by the expression of the transcription factor PPARγ, is heavily dependent on the 
presence of FoxO1 and FoxA3, respectively, since siRNA against either of them completely 
obliterate the stimulatory effect of vitamin K2 obtained through its binding to SXR. However, 
the literature in general advocates a plethora of PIK3/Akt-stimulated transcription factors of 
the FoxA and FoxO families in the cascade of insulin/IGF-1 mediated signaling in general. 
However, the present data show, for the first time that vitamin K2 (i.e., the MK-7 variant) 
directly stimulates FoxO1 and FoxA3, short-cutting the insulin/IGF-1 activation cascade. The 
assertion to be drawn is simply: Vitamin K2 may directly fortify the action of insulin, thus 
ensuring a better glucose homeostasis, as well as protection from a detrimental turnover of 
lipids and protein structures of the body.
Figure 3. The impact of vitamin K2 (in the form of MK-7) on the signaling mechanism of insulin, via the PIK3/Akt/
FoxO/FoxA cascade. Left panel: MK-7, bound to the transcription factor SXR activates FoxO1 and FoxA3, with ensuing 
stimulation of Sirt1. Right panel: Expression (mRNA analyses) of the transcription factor PPARγ in adipocytes generated 
from stem cells, either stimulated by vitamin K2 (MK-7) or inhibited in the presence of siRNA against FoxO1 or FoxA3. 
Reference to the figures: Left – DN Gross et al. (Oncogene, 2320–2336, 2008); Michael P. Czech (PNAS, 11198–11200, 
September 30, 2003).
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3. SXR cross talks with biological signals in biological responses: 
implications in health and disease
3.1. The molecular mechanisms of SXR-mediated gene repression
Currently, SXR has been described as a repressor of gluconeogenic gene expression, some 
of which are glucose-6-phosphatase (G6Pase) and phosphoenolpyruvate carboxykinase 1 
(PEPCK1), thus implicating vitamin K2 in metabolic (energy-related) reactions taking place in 
the liver [23–25]. The SXR-vitamin K2 complex may therefore interfere directly with transcrip-
tion factors and thus be rendered responsive to both insulin and glucagon. Consequently, 
one would observe a release of transcription factors with their coactivators from target genes, 
which would lead to a general subactivation of gene transcription.
Furthermore, it has been asserted that SXR represses the CYP-genes through interference with 
the vitamin D receptor, VDR [26]. Hence, in tissues short of vitamin D3, liganded SXR would 
associate directly to vitamin D response elements (VDREs) and modulate transcription. 
Therefore, it may be asserted that vitamin K2 and vitamin D, as well as vitamin A (via VDR 
and RXA, respectively), and many other transcription factor like molecules (e.g., PPARs, FXR, 
LXRα, LRH-1 = NR5A2, RXR), when associated with their ligands, may act synergistically 
on gene transcription in general [16, 27–29]. Hence, it is not straightforward to predict the 
net results of a certain combination of liganded transcription factors on biological processes. 
However, there are several excellent reports on the impact of vitamin K2, in association with 
the nuclear factor SXR, on cellular metabolism.
3.2. Involvement of SXR in metabolic functions
Xenobiotics are able to enhance SXR-mediated expression of xenobiotic-metabolizing enzymes 
in both the liver and intestines. Even though such a modulation normally serves to detoxify 
the xenobiotics in question, these “alien molecules” enhance the production of intermediates, 
which confer harmful attack of tissues on the body [30, 31]. Additionally, SXR affects the bal-
ance of endobiotics (e.g., steroid hormones, cholesterols, and bile acids) aided by the same 
biochemical pathways. Hence, an SXR activation will consequently stimulate a plethora of 
physiological responses, i.e., in the liver, which plays an important role in the processing of, 
among many substances, glucose and lipids. Disruption of their metabolic fate may result 
in diseases, of which type II diabetes (T2DM) and obesity are most frequently encountered. 
Newly published studies of SXR-KO and SXR-humanized animals clearly shed light on the 
metabolic functions of SXR in man.
3.3. SXR and its role in energy metabolism of the liver
The liver provides energy sources to the rest of the body, i.e., carbohydrates and lipids are 
catabolized in order to fuel both central and peripheral tissues and organs. The effect of SXR 
on hepatic energy turnover was discovered with the aid of SXR-KO mice [25, 32, 33].
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3.4. SXR in glucose handling
The pancreatic hormones (insulin and glucagon) reciprocally regulate the blood glucose 
level via transcriptional processes, where rate-limiting enzymes like G6Pase and PEPCK1 
in the glucose metabolism play a decisive role [34–36]. The glucose-6-phosphatase dephos-
phorylates glucose-6-phospate (G6P), constituting the endpoint of both the glucose-forming 
and glucose-utilizing reactions, while PEPCK1 converts oxaloacetate to phosphoenolpyru-
vate (PEP) in the gluconeogenic reaction. These enzymes are instrumental in controlling 
blood glucose levels. During fasting and/or prolonged exercise, glucagon dominates glu-
cose metabolism by activating the cAMP/PKA signaling pathway [35, 37, 38]. When phos-
phorylated by PKA, the cAMP-response element-binding protein (CREB) stimulates both 
the G6Pase and PEPCK1.
However, insulin acts in an opposite manner, and in response to high blood glucose levels, 
insulin is secreted and activates the phosphoinositide 3-kinase (PI3K)/Akt signaling pathway 
[39]. Thereafter, Akt phosphorylates and inactivates the transcription factor forkhead box O1 
(FoxO1). FoxO1, being a key regulator of glucose turnover, subsequently stimulates the insu-
lin response sequence (IRS)-bearing genes G6Pase and PEPCK1 [40]. When phosphorylation 
by Akt, FoxO1 cannot longer translocate to the nucleus, it is rapidly acetylated and therefore 
loses its activity [41, 42].
But, when using SXR-KO and SXR-humanized animals, it has been demonstrated that SXR 
is an important regulator of xenobiotic-dependent glucose turnover in the liver. Treatment 
of mice with potent SXR activators consistently leads to lowered blood glucose levels in 
laboratory animals [32]. Furthermore, it was shown that there existed so-called “cross-talk” 
between SXR and FoxO1 as a molecular mechanism underlying the downregulation of glucose 
metabolism [18]. It was reported by Kodama and Negishi that liganded SXR directly interacts 
with phosphorylated CREB in primary hepatocytes [25], and that SXR disturbs the binding 
of CREB to CRE with an ensuing repression of the CREB-mediated transcription of G6Pase 
and PEPCK1 genes. Looking at hitherto available information, it can be asserted that SXR, by 
“targeting” a plethora of factors modulated by insulin and glucagon, leads to an activation of 
many genes being functional in the intrinsic regulatory machinery maintaining serum glucose 
levels within “healthy” limits.
3.5. SXR in lipid turnover
The liver provides lipid-derived energy-rich compounds to different parts of the body. 
Hepatic lipid metabolism is controlled by the net influence of the “reciprocal” hormones 
insulin and glucagon, as well as by nutritional conditions. Some 10 years ago, Kodama 
and Negishi, along with Nakamura [25, 32], published that treatment with PCN (an activa-
tor of SXR) decreased the mRNA levels of carnitine palmitoyltransferase 1a (CPT1a) and 
3-hydroxy-3-methylglutarate-CoA synthase 2 (Hmgcs2) in livers of starved wild-type mice, 
but not in SXR-KO mice [32]. CPT1a is instrumental in the overall mitochondrial β-oxidation 
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by funneling long-chain fatty acids into mitochondria [43], and the mitochondrial enzyme 
HMGCS2 facilitates the initial reaction of ketogenesis [44].
Additionally, the stimulation of SXR by PCN has been demonstrated to enhance the mRNA 
steady state level of stearoyl-CoA desaturase 1 (Scd1) in hepatic tissue of starved wild-type 
experimental animals. SCD1, which serves as a key enzyme in hepatic lipogenesis, facilitates 
the rate-limiting step in the synthesis of unsaturated fatty acids [45]. The plasma concen-
trations of 3-OH-butylate were decreased, while the hepatic level of triglyceride (TG) was 
increased by the PCN treatment in wild-type mice during assay conditions. However, neither 
TG nor cholesterol levels in the blood were altered in those animals, despite the fact that there 
was a significant rise in TG accumulated in their liver. Hence, as a means of survival during 
fasting, SXR is thought to slow down hepatic lipid turnover by repressing β-oxidation and 
ketogenesis, while stimulating the transcription of lipogenic enzymes, in much the same way 
as induced by insulin.
The Akt-regulated forkhead transcription factor FoxA2 which serves as a facilitator of insu-
lin-dependent modulation of β-oxidation and ketogenesis, enhances expression of both the 
CPT1a and HMGCS2 gene, respectively [21, 46]. It is well known that Insulin activates the 
PI3K/Akt signaling pathway to phosphorylate FoxA2, in order to translocate it from nucleus 
to cytosol, thereby downregulating both the genes. And, it has been asserted that a direct 
interaction between SXR and FoxA2 serves as the mechanism, by which SXR represses the 
transcription of CPT1a and HMGCS2 in the liver [32].
A plethora of transcription factors and coregulators have been asserted to serve as modulators 
of hepatic lipid metabolism, e.g., the peroxisome proliferator-activated receptors (PPARs), the 
liver X receptor α (LXRα), as well as the sterol regulatory element-binding proteins (SREBPs) 
[47]. The expression of SREBP1c, which is construed as the dominant regulator of hepatic 
lipogenesis, is under the control of LXRα, and mediates the insulin- and fatty acids-depen-
dent responses of lipogenic genes such as fatty acid synthase (FAS), acetyl-CoA carboxylase 1 
(ACC1), stearoyl-CoA-desaturase-1 (SCD1), and fatty acid elongase (FAE). SXR is believed to 
upregulate lipogenesis in the liver, independently of SREBP1c action, and it is not deemed to 
be associated with the steady state expression levels of both the Fas and Acc1 genes. Among 
the cluster of lipogenic genes, Cd36 (cluster of differentiation 36) is deemed to be serve as a 
direct target of SXR in the liver. And, upon stimulation by ligands, the receptor is believed to 
become recruited to a DR3-type SXR response element within its promoter region of the liver 
of experimental animals [48]. Furthermore, SXR has been asserted to serve as a link, facilitating 
the upregulation of the Pparγ-gene, which functions as a strong regulator of lipid-synthesizing 
enzymes [48]. Such a cross-talk involving nuclear receptors should confer a significant impact 
on the body’s lipid homeostasis. Our data are in line with the published literature, however, it 
should be asserted that SXR probably affects a larger spectrum of FoxO and FoxA species than 
those presented in this review. In this way, one might speculate that SXR is able to recruit a 
“moving” representation of these transcription factors simultaneously, and that the net effect 
on various cell phenotypes depends on: (1) the distribution of FoxOs and FoxAs at any time 
within the cell or tissue, as well as (2) the epigenetic machinery or “make up” at any time 
within the same cells or tissues.
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4. The effect of vitamin K2 on other genes related to metabolic processes 
in the cell
In 2009, Slatter [49] and coworkers published a paper, featuring oligonucleotide microarrays 
with the intention to reveal the heterogeneity of drug metabolism associated gene expression in 
liver tissue from healthy humans. Their intention was to define clusters of so-called “absorption, 
distribution, metabolism, and excretion” = ADME genes to define subgroups of coregulated 
genes. When analyzing the gene sets, they discovered distinct patterns of “parallel” gene expres-
sions featuring gene “clusters”, which proved to be modulated by the nuclear receptor SXR. So 
called “fold range metrics and frequency distributions” were applied in order to reveal the vari-
ability of solitary PKDM genes. The most variable gene entities chiefly correlated to: (1) drug 
metabolism, (2) intermediary metabolism, (3) inflammation, and (4) cell cycle control. Unique 
expression patterns of these genes allowed for a further correlation with a parallel expression 
of a plethora of other genes. Of major interest was the identification of SXR responsive genes.
A comprehensive list of these genes can be found in the article, however, quite a few of which 
are related to metabolic processes in the cell. The genes are the following (in alphabetical order): 
CLOCK, DUSP7, GCDH, IGFBP2, MAP2K2, NUCB2, OGT, PFKB1, PTPN11, and SLC16A2. By 
“looking up” current descriptions of the genes in “Gene-Cards”, the following features of these 
SXR-sensitive genes were obtained (of which parts of their description is cited as presented):
Name of gene Description of cellular function(s)
http://www.genecards.org/cgi-bin/carddisp.pl?gene=NR1I2
CLOCK Clock circadian regulator (The protein encodes a transcription factor, and serves as DNA-binding 
histone acetyl transferase). Interpretation: Polymorphisms in this gene may be associated with 
obesity and metabolic syndrome. CLOCK normally regulates gene products (proteins) in an 
optimal fashion, adapted to diurnal demands on the body related to food ingestion, physical 
activity and recreation/sleep.
DUSP7 Dual-specific phosphatase (DUSPs) constitutes a large subgroup of cysteine-base protein-
tyrosine phosphatases characterized by their ability to dephosphorylate both tyrosine and serine/
threonine residues. Interpretation: DUSP7 may function as a modulator of cellular exposure to 
insulin and growth factors, ensuring energy homeostasis within optimal limits.
GCDH The protein encoded by this gene belongs to the acyl-CoA dehydrogenase family. It catalyzes the 
oxidative carboxylation of glutaryl-CoA to crotonyl-CoA and CO
2
 in the degradative pathway of 
L-lysine, L-hydroxylysine, and L-tryptophan metabolism. Interpretation: GCDH is involved in the 
stability of mitochondria, and hence energy metabolism in general.
IGFBP2 Insulin-like growth factor binding protein, type 2. This protein inhibits IGF-mediate growth.
Interpretation: A reduction in IGFBP2 may be responsible for organ hyperplasia and the 
development of neoplasia (cancer).
MAP2K2 This MAP-kinase catalyzes the concomitant phosphorylation of a threonine and a tyrosine 
residue in a Thr-Glu-Tyr sequence located in MAP-kinases. It activates the ERK1 and ERK2 MAP-
kinases (by similarity). Interpretation: This kinase may block tumorigenesis and normalize energy 
metabolism via MEK1/2 and the FoxO- and FoxA-family of transcription factors.
NUCB2 Anorexigenic peptide; seems to play an important role in hypothalamic pathways regulating 
food intake and energy homeostasis, acting in a leptin-dependent manner. Interpretation: Appetite 
regulator fortifying the effect of leptin, but independent of the size of fat depots.
The Impact of Vitamin K2 on Energy Metabolism
http://dx.doi.org/10.5772/67152
93
Author details
Mona Møller1*, Serena Tonstad2, Tone Bathen3 and Jan Oxholm Gordeladze4
*Address all correspondence to: mona.moller@kappabio.com
1 KappaBio, Oslo, Norway
2 Ullevål Hospital, Oslo, Norway
3 NTNU, Trondheim, Norway
4 University of Oslo, Oslo, Norway
References
[1] Virtanen KA, Lidell ME, Orava J, Heglind M, Westergren R, Niemi T, Taittonen M, Laine 
J, Savisto NJ, Enerback S, et al. Different metabolic responses of human brown adipose 
tissue to activation by cold and insulin. Engl. N. Med. J. 360 (2009) 1518–1525.
[2] Gesta S, Tseng YH, Kahn CR. Developmental origin of fat: tracking obesity to its source. 
Cell. 131 (2007) 242–256.
OGT Glycosylates a substantial and diverse amount of proteins, encompassing species like histone 
H2B, AKT1 and PFK (phosphofructokinase). It can modulate their cellular processes through 
cross-talk between processes like glycosylation and phosphorylation, or via proteolytic 
processing. Involved in insulin sensitivity in muscle cells and adipocytes by glycosylating 
components of insulin signaling, blocks phosphorylation of AKT1, stimulates IRS1 
phosphorylation, as well as attenuating insulin signaling. Interpretation: Modulator of insulin and 
IGF-1 signaling/sensitivity to maintain a healthy muscle tissue fat mass and distribution.
PFKFB1 Encodes a member of the family of the bifunctional 6-phophofructo-2 kinase: fructose-2, 
6-bisphosphatase enzymes. These enzymes form homodimers, which catalyze the synthesis, 
as well as the degradation of fructose 2, 6-bishosphate, via independent catalytic domains. 
Fructose-2, 6-bisphosphate serves as the activator of the glycolytic pathway, and as the inhibitor 
of the gluconeogenetic pathway. Interpretation: Regulating fructose-2,6-bisphosphate levels 
through the activity of this enzyme is thought to regulate glucose homeostasis. Multiple 
alternatively spliced transcript variants have been found for this gene.
PTPN11 PTP (protein tyrosine phosphatase) is a member a large family of phosphatases and plays a 
regulatory role in various cell signaling events that are important for a diversity of cell functions, 
such as mitogenic activation, metabolic control, transcription regulation, and cell migration. 
Interpretation: Because of the activating effects of PTPN11 on ERK (extracellular signal regulated 
kinase), a lack of PTPN11 activation may lead to adiposity, diabetes, and hyperleptinemia.
SLC16A2 Very active and specific thyroid hormone transporter molecule. Stimulates cellular uptake of 
thyroxine (T4), triiodothyronine (T3), reverse triiodothyronine (rT3), and diiodothyronine. 
Interpretation: Lack of SLC16A2 activation may lead to a reduction in uptake and biological 
functions of T4 and T3, which is associated with adiposity, diabetes, and hyperleptinemia.
Vitamin K2 - Vital for Health and Wellbeing94
[3] Lowell BB, Susulic VS, Hamann A, Lawitts JA, Himms-Hagen J, Boyer BB, Kozak LP, 
Flier JS. Development of obesity in transgenic mice after genetic ablation of brown adi-
pose tissue. Nature. 366 (1993) 740–742.
[4] Seale P, Bjork B, Yang W, Kajimura S, Chin S, Kuang S, Scime A, Devarakonda S, Conroe 
HM, Erdjument-Bromage H, et al. PRDM16 controls a brown fat/skeletal muscle switch. 
Nature. 454 (2008) 961–967.
[5] Wu J, Bostrom P, Sparks LM, Ye L, Choi JH, Giang AH, Khandekar M, Virtanen KA, 
Nuutila P, Schaart G, et al. Beige adipocytes are a distinct type of thermogenic fat cell in 
mouse and human. Cell. 150 (2012) 366–376.
[6] Fisher FM, Kleiner S, Douris N, Fox EC, Mepani RJ, Verdeguer F, Wu J, Kharitonenkov 
A, Flier JS, Maratos-Flier E, et al. FGF21 regulates PGC-1α and browning of white adi-
pose tissues in adaptive thermogenesis. Genes Dev. 26 (2012) 271–281.
[7] Bostrom P, Wu J, Jedrychowski MP, Korde A, Ye L, Lo JC, Rasbach KA, Bostrom EA, 
Choi JH, Long JZ, et al. A PGC1-α-dependent myokine that drives brown-fat-like devel-
opment of white fat and thermogenesis. Nature. 481 (2012) 463–468.
[8] Cederberg A, Gronning LM, Ahren B, Tasken K, Carlsson P, Enerback S. FOXC2 is a winged 
helix gene that counteracts obesity, hypertriglyceridemia, and diet-induced insulin resis-
tance. Cell. 106 (2001) 563–573.
[9] Seale P, Conroe HM, Estall J, Kajimura S, Frontini A, Ishibashi J, Cohen P, Cinti S, 
Spiegelman BM. Prdm16 determines the thermogenic program of subcutaneous white 
adipose tissue in mice. J. Clin. Invest. 121 (2011) 96–105.
[10] Ohno H, Shinoda K, Spiegelman BM, Kajimura S. PPARγ agonists induce a white-to-
brown fat conversion through stabilization of PRDM16 protein. Cell Metab. 15 (2012) 
395–404.
[11] Qiang L, Wang L, Kon N, Zhao W, Lee S, Zhang Y, Rosenbaum M, Zhao Y, Gu W, Farmer 
SR, et al. Brown remodeling of white adipose tissue by SirT1-dependent deacetylation of 
Pparγ. Cell. 150 (2012) 620–632.
[12] Cohen P, Levy JD, Zhang Y, Frontini A, Kolodin DP, Svensson KJ, Lo JC, Zeng X, Ye L, 
Khandekar MJ, et al. Ablation of PRDM16 and beige adipose causes metabolic dysfunc-
tion and a subcutaneous to visceral fat switch. Cell. 156 (2014) 304–316.
[13] Lecka-Czernik B, Stechschulte LA. Protein Phosphatase PP5 Controls Bone Mass and 
the Negative Effects of Rosiglitazone on Bone through Reciprocal Regulation of PPARγ 
(Peroxisome Proliferator-activated Receptor γ) and RUNX2 (Runt-related Transcription 
Factor 2). Arch. Biochem. Biophys. 561 (2014) 124–129.
[14] Aguirre L, Napoli N, Waters D, Qualls C, Villareal DT, Armamento-Villareal R. Increasing 
adiposity is associated with higher adipokine levels and lower bone mineral density in 
obese older adults. Clin. J. Endocrinol. Metab. 99(9) (2014) 3290–3297.
The Impact of Vitamin K2 on Energy Metabolism
http://dx.doi.org/10.5772/67152
95
[15] Compston J. Obesity and bone. Curr. Osteoporos. Rep. 11 (2013) 30–35.
[16] Zhou C, Verma S, Blumberg B. The steroid and xenobiotic receptor (SXR), beyond xeno-
biotic metabolism. Nucl. Recept. Signal. 7 (2009) 1–21.
[17] Montminy M, and Koo SH. PGC-1 promotes insulin resistance in liver through PPAR-
alpha-dependent induction of TRB-3. Diabetes: outfoxing insulin resistance? Nature. 432 
(2004) 958–9.
[18] Kodama S, Koike C, Negishi M. and Yamamoto Y. Nuclear receptors CAR and PXR cross 
talk with FOXO1 to regulate genes that encode drug-metabolizing and gluconeogenic 
enzymes. Mol. Cell. Biol. 24 (2004) 7931–40.
[19] Miao J, Fang S, Bae Y. and Kemper JK. Functional inhibitory cross-talk between consti-
tutive androstane receptor and hepatic nuclear factor-4 in hepatic lipid/glucose metab-
olism is mediated by competition for binding to the DR1 motif and to the common 
coactivators, GRIP-1 and PGC-1alpha. J. Biol. Chem. 281 (2006) 14537–46.
[20] Eaton S, Bartlett K. and Pourfarzam M. Mammalian mitochondrial β-oxidation. Biochem 
J. 320 (Pt 2) (1996) 345–57.
[21] Wolfrum C, Asilmaz E, Luca E, Friedman JM. and Stoffel M. Foxa2 regulates lipid 
metabolism and ketogenesis in the liver during fasting and in diabetes. Nature. 432 
(2004) 1027–32.
[22] Kiyosawa N, Tanaka K, Hirao J, Ito K, Niino N, Sakuma K, Kanbori M, Yamoto T, 
Manabe S. and Matsunuma N. Molecular mechanism investigation of phenobarbital-
induced serum cholesterol elevation in rat livers by microarray analysis. Arch. Toxicol. 
78 (2004) 435–42.
[23] Bhalla S, Ozalp C, Fang S, et al. Ligand-activated pregnane X receptor interferes with 
HNF-4 signaling by targeting a common coactivator PGC-1a. Functional implications in 
hepatic cholesterol and glucose metabolism. J. Biol. Chem. 279 (2004) 45139–45147.
[24] Kodama S, Koike C, Negishi M, Yamamoto Y. Nuclear receptors CAR and PXR cross 
talk with FOXO1 to regulate genes that encode drug-metabolizing and gluconeogenic 
enzymes. Mol. Cell. Biol. 24 (2004) 7931–7940.
[25] Kodama S, Moore R, Yamamoto Y, Negishi M. Human nuclear pregnane X receptor 
cross-talk with CREB to repress cAMP activation of the glucose-6-phosphatase gene. 
Biochem. J. 407 (2007) 373–381.
[26] Konno Y, Kodama S, Moore R, et al. Nuclear xenobiotic receptor pregnane X recep-
tor locks corepressor silencing mediator for retinoid and thyroid hormone receptors 
(SMRT) onto the CYP24A1 promoter to attenuate vitamin D3 activation. Mol. Pharmacol. 
75 (2009) 265–271.
[27] Francis GA, Fayard E, Picard F, and Auwerx J. Nuclear Receptors and the Control of 
Metabolism. Ann. Rev. Physiol. 65 (2003) 261–311.
Vitamin K2 - Vital for Health and Wellbeing96
[28] Bügel S ,Vitamin K, and bone health in adult humans. Vitam. Horm. 78 (2008) 393–416.
[29] Ahmadieh H, Arabi A. Vitamins and bone health: beyond calcium and vitamin D. Nutr 
Rev. 69(10); (2011) 584–598. doi: 10.1111/j.1753-4887.2011.00372.x.
[30] Cheng J, Ma X, Krausz KW, et al. Rifampicin-activated human pregnane X receptor and 
CYP3A4 induction enhance acetaminopheninduced toxicity. Drug Metab. Dispos. 37 
(2009) 1611–1621.
[31] Guo GL, Moffit JS, Nicol CJ, et al. Enhanced acetaminophen toxicity by activation of the 
pregnane X receptor. Toxicol. Sci. 82 (2004) 374–380.
[32] Nakamura K, Moore R, Negishi M, Sueyoshi T. Nuclear pregnane X receptor cross-talk 
with FoxA2 to mediate drug-induced regulation of lipid metabolism in fasting mouse 
liver. J. Biol. Chem. 282 (2007) 9768–9776.
[33] Zhou J, Zhai Y, Mu Y, et al. A novel pregnane X receptormediated and sterol regula-
tory element-binding protein-independent lipogenic pathway. J. Biol. Chem. 281 (2006) 
15013–15020.
[34] Hanson RW, Reshef L. Regulation of phosphoenolpyruvate carboxykinase (GTP) gene 
expression. Annu. Rev. Biochem. 66 (1997) 581–611.
[35] Jiang G, Zhang BB. Glucagon and regulation of glucose metabolism. Am. J. Physiol. 
Endocrinol. Metab. 284 (2003) E671–E678.
[36] van Schaftingen E, Gerin I. The glucose-6-phosphatase system. Biochem. J. 362 (2002) 
513–532.
[37] Gonzalez GA, Montminy MR. Cyclic AMP stimulates somatostatin gene transcription 
by phosphorylation of CREB at serine 133. Cell. 59 (1989) 675–680.
[38] Herzig S, Long F, Jhala US, et al. CREB regulates hepatic gluconeogenesis through the 
coactivator PGC-1. Nature. 413 (2001) 179–183.
[39] Taniguchi CM, Emanuelli B, Kahn CR. Critical nodes in signalling pathways: Insights 
into insulin action. Nat. Rev. Mol. Cell Biol. 7 (2006) 85–96.
[40] Barthel A, Schmoll D, Unterman TG. FoxO proteins in insulin action and metabolism. 
Trends Endocrinol. Metab. 16 (2005) 183–189.
[41] Matsuzaki H, Daitoku H, Hatta M, et al. Acetylation of Foxo1 alters its DNA-binding abil-
ity and sensitivity to phosphorylation. Proc. Natl. Acad. Sci. USA. 102 (2005) 11278–11283.
[42] Schmoll D, Walker KS, Alessi DR, et al. Regulation of glucose-6-phosphatase gene 
expression by protein kinase Ba and the forkhead transcription factor FKHR. Evidence 
for insulin response unit-dependent and independent effects of insulin on promoter 
activity. J. Biol. Chem. 275 (2000) 36324–36333.
[43] Louet JF, Le May C, Pegorier JP, et al. Regulation of liver carnitine palmitoyltransferase 
I gene expression by hormones and fatty acids. Biochem. Soc. Trans. 29 (2001) 310–316.
The Impact of Vitamin K2 on Energy Metabolism
http://dx.doi.org/10.5772/67152
97
[44] Hegardt FG. Mitochondrial 3-hydroxy-3-methylglutaryl-CoA synthase: A control 
enzyme in ketogenesis. Biochem. J. 338 (1999) 569–582.
[45] Flowers MT, Ntambi JM. Role of stearoyl-coenzyme A desaturase in regulating lipid 
metabolism. Curr. Opin. Lipidol. 19 (2008) 248–256.
[46] Wolfrum C, Asilmaz E, Luca E, et al. Foxa2 regulates lipid metabolism and ketogenesis 
in the liver during fasting and in diabetes. Nature. 432 (2004) 1027–1032.
[47] Weickert MO, Pfeiffer AF. Signalling mechanisms linking hepatic glucose and lipid 
metabolism. Diabetologia. 49 (2006) 1732–1741.
[48] Zhou J, Zhai Y, Mu Y, et al. A novel pregnane X receptormediated and sterol regula-
tory element-binding protein-independent lipogenic pathway. J. Biol. Chem. 281 (2006) 
15013–15020.
[49] Slatter JG, Templeton IE, Castle JC, Kulkarni A, Rushmore TH, Richards K, He Y, Dai X, 
Cheng OJ, Caguyang M, Ulrich RG. Compendium of gene expression profiles compris-
ing a baseline model of the human liver drug metabolism transcriptome. Xenobiotica. 
36(10-11) (2006) 938–962.
Vitamin K2 - Vital for Health and Wellbeing98
